Arunjyoti Bio Ventures Posts ₹61.24 Lakh Q1 Profit

Arunjyoti Bio Ventures Limited has announced a net profit of ₹61.24 lakh for the first quarter ended 30 June 2026. This marks a significant turnaround for the company, which had reported a net loss of ₹540.09 lakh in the preceding quarter.

The company's revenue from operations stood at ₹820.00 lakh for the quarter, representing an increase from the ₹723.73 lakh reported in the previous quarter. This growth in revenue has contributed to the company's return to profitability.

In addition to the financial results, the board of directors has approved a proposal to change the company's name from Arunjyoti Bio Ventures Limited to Pasura Industries Limited. This change is subject to approval from shareholders and is expected to be implemented in the near future.

The board has also waived the recovery of an aggregate excess managerial remuneration of ₹25.19 lakh paid to whole-time directors Pabbathi Badhri Narayana Murthy and Nadimpalli Vishal for the financial year 2025-26. This waiver requires shareholder approval and is intended to support the company's efforts to retain and motivate its key personnel.

Furthermore, the company has revised the remuneration for its whole-time directors. Pabbathi Badhri Narayana Murthy's monthly remuneration will be ₹8.00 lakh, plus a leave travel allowance of up to ₹10.00 lakh per annum. Nadimpalli Vishal and Pabbathi Dathvik will each receive ₹5.00 lakh per month, with a leave travel allowance of up to ₹10.00 lakh per annum.

The company has also announced changes to its secretarial auditor, with Manoj Parakh & Associates resigning and Vivek Surana & Associates being appointed to fill the casual vacancy. The 40th Annual General Meeting for the financial year 2025-26 is scheduled to be held on 12 August 2026, through video conference or other audio-visual means.

Arunjyoti Bio Ventures Limited is a Mumbai-based company that operates in the bio ventures sector. The company's financial results and board decisions are closely watched by investors and industry analysts, as they provide insight into the company's performance and future prospects.

The company's return to profitability and the proposed name change are significant developments that are expected to impact the company's operations and investor sentiment. The revised remuneration for whole-time directors and the changes to the secretarial auditor are also important decisions that will shape the company's governance and compliance framework.

In the context of the Indian bio ventures sector, Arunjyoti Bio Ventures Limited's financial results and board decisions are part of a larger trend of growth and consolidation. The sector has seen significant investment and innovation in recent years, driven by government initiatives and private sector participation.

Overall, Arunjyoti Bio Ventures Limited's Q1 financial results and board decisions provide a positive outlook for the company's future prospects. The company's return to profitability, proposed name change, and revised remuneration for whole-time directors are all significant developments that are expected to contribute to the company's growth and success.

The implications of these developments for Mumbai and the broader Indian economy are also significant. The bio ventures sector is an important contributor to India's economic growth and development, and companies like Arunjyoti Bio Ventures Limited play a critical role in driving innovation and investment in the sector. As the company continues to grow and evolve, it is likely to have a positive impact on the local economy and community, creating jobs and opportunities for residents and businesses in Mumbai.